For preclinical pharmacology and toxicology studies to succeed, it’s essential that investigators and their teams use best practices for animal enrichment and environmental enhancement. Animal stress — which can stem from lack of trust in the researchers or an inability to express natural, species-specific behaviors — can compromise study data.
Inhaled medicines play an essential role in treating respiratory conditions and many other diseases, from pulmonary fibrosis to asthma. However, a dose of inhaled medicine often results in a cough — an adverse reaction that can be both uncomfortable and counterproductive. It’s a reaction that drug developers seek to avoid as they develop the next […]
In a key study published in the September 2017 issue of Human Gene Therapy Clinical Development, Lovelace Biomedical researchers found that delivering AAV gene therapy for cystic fibrosis by inhalation was both feasible and safe.
Lovelace Biomedical designed a nose-only inhalation exposure system to evaluate an investigational microRNA-based therapy for pulmonary fibrosis — and through its findings, has helped to further advance a novel approach to treating a long-underserved disease.
For pharmaceutical and biotech companies, rare diseases present huge market opportunities — but also, potentially daunting development challenges.
To advance a gene or cell therapy product into clinical trials, drug developers must first gain a thorough understanding of how the agent travels through the body and to the target (or off-target) organs. Beyond this, qPCR can be used to evaluate vector shedding of gene therapies in body fluids and excreta, and provide a basis for which to evaluate transgene expression in the presence of vector.
Lovelace Biomedical’s scientific team will share two recent examples of their advanced preclinical work in defining animal models for radiation research at the upcoming Radiation Research Society’s annual meeting, Oct. 15-18 in Cancun, Mexico.
It was nearly a century ago, in 1918, that an influenza pandemic swept the world, killing as many as 40 million people. The “Spanish Flu,” as it was known, ended up causing nearly 675,000 deaths in the U.S., as it was a strain that quickly converted to pneumonia at a time when antibiotic drugs weren’t available.
The Lovelace team has been performing cigarette-smoke inhalation exposure studies for more than 25 years, ranging from characterization of smoke to comparison of whole-body and nose-only exposure systems. We also are experts in measuring the toxicological effects of cigarette smoke inhalation exposure, using a variety of innovative methods and models depending on the needs of the study.
Get an inside look into a 15-year collaboration between the scientists at Lovelace Biomedical and engineers at Capsugel, a company that develops and manufactures dosage forms for the biopharmaceutical and consumer health industries.